Guopei Luo

Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Venues

Endocrine

Trials

International journal of cancer

Cancer control : journal of the Moffitt Cancer Center

Fudan University Shanghai Cancer Center

Huashan Hospital Fudan University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fudan University Shanghai Cancer Center

China

Associate Professor :: Department of Pancreatic Surgery

Fudan University Shanghai Cancer Center

China

Attending :: Department of Pancreatic Surgery

Fudan University Shanghai Cancer Center

China

Resident :: Department of Pancreatic Surgery

Education History

Huashan Hospital Fudan University

China

PHD :: Department of General Surgery

University of California Irvine School of Medicine

United States

PHD

Publications

Xinyue Wang, Xinzhe Zhu, Yi Liu, He Liu, Zhiwen Xiao, Guopei Luo
Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial. Trials 25 (1) (2024)
Xinyue Wang, Xinzhe Zhu, Yi Liu, He Liu, Zhiwen Xiao, Guopei Luo
Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial. Trials 25 (1) (2024)
Xinyue Wang, Xinzhe Zhu, Yi Liu, He Liu, Zhiwen Xiao, Guopei Luo
Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial. Trials 25 (1) (2024)
Zhiwen Xiao, Huaxiang Xu, Jonathan R Strosberg, Renquan Lu, Xinzhe Zhu, Shengming Deng, Lei Ding, Quanxing Ni, Andrew L Warshaw, Xian-Jun Yu, Guopei Luo
EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms. International journal of cancer (2023)
Xinzhe Zhu, Huaxiang Xu, Zhiwen Xiao, He Liu, Quanxing Ni, Xianjun Yu, Guopei Luo
Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. Endocrine 79 (2) (2023)
Xinzhe Zhu, Huaxiang Xu, Zhiwen Xiao, He Liu, Quanxing Ni, Xianjun Yu, Guopei Luo
Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. Endocrine 79 (2) (2023)
Zhiwen Xiao, Huaxiang Xu, Jonathan R Strosberg, Renquan Lu, Xinzhe Zhu, Shengming Deng, Lei Ding, Quanxing Ni, Andrew L Warshaw, Xianjun Yu, Guopei Luo
EGFR is A Potential Therapeutic Target for Highly Glycosylated and Aggressive Pancreatic Neuroendocrine Neoplasms. International journal of cancer (2023)
Xinzhe Zhu, Huaxiang Xu, Zhiwen Xiao, He Liu, Quanxing Ni, Xianjun Yu, Guopei Luo
Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. Endocrine (2023)
Pin Zhang, Zhiwen Xiao, Huaxiang Xu, Xinzhe Zhu, Lei Wang, Dan Huang, Yun Liang, Quanxing Ni, Jie Chen, Xianjun Yu, Guopei Luo
Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms. Endocrine 77 (2) (2022)
Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Yunzhen Qian, He Cheng, Kaizhou Jin, Quanxing Ni, Xian-Jun Yu, Chen Liu
Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients. Cancer management and research 12 (2020)
Chen Liu, He Cheng, Kaizhou Jin, Zhiyao Fan, Yitao Gong, Yunzhen Qian, Shengming Deng, Qiuyi Huang, Quanxing Ni, Xianjun Yu, Guopei Luo
Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Cancer control : journal of the Moffitt Cancer Center 27 (1) (2020)

Guopei Luo.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Guopei Luo